Display options
Cite
Runfeng L, Yunlong H, Jicheng H, et al. Corrigendum to: Lianhuaqingwen exerts anti-viral and anti-inflammatory activity against novel coronavirus (SARS-CoV-2) [Pharmacol. Res. 156 (2020) 104761]. Pharmacol Res. 2021;174:105907doi: 10.1016/j.phrs.2021.105907.
Runfeng, L., Yunlong, H., Jicheng, H., Weiqi, P., Qinhai, M., Yongxia, S., Chufang, L., Jin, Z., Zhenhua, J., Haiming, J., Kui, Z., Shuxiang, H., Jun, D., Xiaobo, L., Xiaotao, H., Lin, W., Nanshan, Z., & Zifeng, Y. (2021). Corrigendum to: Lianhuaqingwen exerts anti-viral and anti-inflammatory activity against novel coronavirus (SARS-CoV-2) [Pharmacol. Res. 156 (2020) 104761]. Pharmacological research, 174105907. https://doi.org/10.1016/j.phrs.2021.105907
Runfeng, Li, et al. "Corrigendum to: Lianhuaqingwen exerts anti-viral and anti-inflammatory activity against novel coronavirus (SARS-CoV-2) [Pharmacol. Res. 156 (2020) 104761]." Pharmacological research vol. 174 (2021): 105907. doi: https://doi.org/10.1016/j.phrs.2021.105907
Runfeng L, Yunlong H, Jicheng H, Weiqi P, Qinhai M, Yongxia S, Chufang L, Jin Z, Zhenhua J, Haiming J, Kui Z, Shuxiang H, Jun D, Xiaobo L, Xiaotao H, Lin W, Nanshan Z, Zifeng Y. Corrigendum to: Lianhuaqingwen exerts anti-viral and anti-inflammatory activity against novel coronavirus (SARS-CoV-2) [Pharmacol. Res. 156 (2020) 104761]. Pharmacol Res. 2021 Dec;174:105907. doi: 10.1016/j.phrs.2021.105907. Epub 2021 Nov 19. PMID: 34802883; PMCID: PMC8603740.
Copy Download .nbib Format: NLM
Share it on

Pharmacol Res. 2021 Dec;174:105907. doi: 10.1016/j.phrs.2021.105907. Epub 2021 Nov 19.

Corrigendum to: Lianhuaqingwen exerts anti-viral and anti-inflammatory activity against novel coronavirus (SARS-CoV-2) [Pharmacol. Res. 156 (2020) 104761].

Pharmacological research

Li Runfeng, Hou Yunlong, Huang Jicheng, Pan Weiqi, Ma Qinhai, Shi Yongxia, Li Chufang, Zhao Jin, Jia Zhenhua, Jiang Haiming, Zheng Kui, Huang Shuxiang, Dai Jun, Li Xiaobo, Hou Xiaotao, Wang Lin, Zhong Nanshan, Yang Zifeng

Affiliations

  1. State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, Guangzhou Institute of Respiratory Health, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, PR China.
  2. Hebei University of Chinese Medicine, College of Integrated Chinese and Western Medicine, China.
  3. Technology Centre, Guangzhou Customs, China.
  4. KingMed Virology Diagnostic & Translational Center, China.
  5. State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, Guangzhou Institute of Respiratory Health, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, PR China; State Key Laboratory of Quality Research in Chinese Medicine, Macau Institute for Applied Research in Medicine and Health, Macau University of Science and Technology, Taipa, Macau, China; KingMed Virology Diagnostic & Translational Center, China. Electronic address: [email protected].

PMID: 34802883 PMCID: PMC8603740 DOI: 10.1016/j.phrs.2021.105907

[No abstract available.]

Publication Types